Veracyte, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing. Veracyte is a diagnostics company offering genomic and immuno-oncology tests, primarily through U.S. CLIA-certified laboratories, and pursuing international IVD sales using the nCounter platform.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Total revenue | $219.5 million | $117.5 million |
| Testing revenue | $188.2 million | $102.0 million |
| Product revenue | $11.5 million | $9.8 million |
| Biopharmaceutical and other revenue | $19.9 million | $5.7 million |
| Operating loss | $81.9 million | $35.4 million |
| Net loss | $75.6 million | $34.9 million |
| Operating cash flow | $(31.6) million | $(9.7) million |
- Revenue grew 87%; diagnostic tests reported increased 88% to 70,449. Total test volume, including product tests sold, rose 77% to 78,565.
- Gross profit was approximately $145.1 million, or 66% of revenue, versus approximately $76.0 million, or 65%, in 2020; calculated as revenue less reported costs of revenue.
- Operating expenses increased 97% to $301.4 million, contributing to a wider operating loss. Net loss per share was $1.11, compared with $0.66.
- Cash and cash equivalents were $173.2 million at year-end, down from $349.4 million. Current assets were $243.1 million and current liabilities $64.2 million.
- Cash used in investing was $739.2 million, principally for Decipher Biosciences ($574.4 million) and HalioDx ($162.4 million). Financing provided $596.3 million, primarily from a February 2021 stock offering with $593.8 million net proceeds.
- Debt principal outstanding was effectively zero; a $1.2 million final debt payment was due in 2022. The company had not drawn its revolving line of credit as of year-end. Total liabilities were $91.3 million and stockholders’ equity was $1.10 billion.
Material changes and notable items
- Decipher Biosciences was acquired in March 2021 and contributed $65.9 million of revenue from acquisition through year-end. HalioDx was acquired in August 2021 and contributed $11.5 million. The acquisitions expanded urology, immuno-oncology, and IVD manufacturing capabilities.
- Biopharmaceutical and other revenue included $4.0 million of Johnson & Johnson collaboration milestone revenue. HalioDx also contributed contract development, manufacturing, and testing revenue.
- Acquisition-related costs and compensation materially affected expenses, including $25.1 million of nonrecurring post-combination compensation expense related to Decipher award acceleration and $11.5 million of HalioDx transaction costs. The filing also reports $27.0 million of acquisition-related stock-based compensation and $20.1 million of professional fees and other transaction costs within general and administrative expense.
- Management revised estimates for collections on prior-period tests and recognized $1.5 million of additional testing revenue in 2021, reducing the reported operating loss by $1.5 million.
- Goodwill rose to $707.9 million, largely from the acquisitions; intangible assets were $202.7 million. No goodwill or intangible-asset impairment was recorded in 2021.
- Medicare represented 30% of revenue and UnitedHealthcare 10%. Private commercial payers accounted for 54% and Medicaid 2%.
Outlook, commentary, and risks
- Management expects additional losses in 2022 and potentially in future years, while stating that year-end cash, available credit, and expected revenue should meet anticipated cash needs for at least the next 12 months. No specific revenue or earnings guidance is provided.
- Management identified test adoption, reimbursement and payer coverage, integration of the acquisitions, international expansion, and adaptation of tests to the nCounter platform as key drivers of future performance.
- COVID-19 continued to affect test volumes and care access, particularly hospital-based Afirma testing and pulmonology tests requiring bronchoscopy. Supply constraints and staffing pressures were additional concerns.
- Key risks include reliance on Afirma and Decipher, payer concentration and potential reimbursement reductions, complex claims collection and revenue estimates, sole-source suppliers, and the need to integrate Decipher and HalioDx successfully.
- Regulatory uncertainty includes possible changes to U.S. oversight of laboratory-developed tests and the EU IVDR transition. The company also cites competition, data privacy and cybersecurity, and foreign-exchange exposure.
- The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting. The assessment excluded Decipher and HalioDx controls; those acquired businesses represented 35% of 2021 revenue.
Most important facts for investors to verify
- Whether revenue growth and test volumes persist after accounting for the partial-year contributions from Decipher and HalioDx.
- Whether payer coverage, reimbursement rates, and cash collections support reported testing revenue; accruals rely on management estimates.
- Whether acquisition integration and planned nCounter kit manufacturing transition deliver expected growth and economics, without impairment or disruption.
- Whether cash burn, acquisition-related obligations, and operating costs remain consistent with management’s stated liquidity outlook.
- How COVID-related demand and supply effects, evolving LDT rules, and EU IVDR requirements affect test access, reimbursement, and commercialization.